Trial Profile
A study evaluating an impact of HIV-1 minority variants on the virus response to a rilpivirine-based first line regimen
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jan 2018
Price :
$35
*
At a glance
- Drugs Rilpivirine (Primary) ; Emtricitabine/tenofovir; Lamivudine/abacavir; Raltegravir
- Indications HIV-1 infections
- Focus Therapeutic Use
- 02 Jan 2018 New trial record
- 13 Dec 2017 Results published in the Clinical Infectious Diseases